Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Orantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 16/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | STK3 | Q13188 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | STK4 | Q13043 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orantinib SCHEMBL134662 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| Orantinib SCHEMBL134661 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| Orantinib SCHEMBL29354645 | 1.00 | FGFR1 (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL12020869 | 0.91 | KDR (0.84) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL25717271 | 0.90 | KDR (0.82) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL26023377 | 0.88 | KDR (0.79) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL13497857 | 0.88 | KDR (0.79) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL4408686 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL29678231 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA | |
| SCHEMBL30676938 | 0.88 | KDR (1.00) | FGFR1KDRPDGFRBFLT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2994130-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | Bush, Andrew B. (US) | 2016-03-16 | — | — | EP | claimed |
| WO-2014182277-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2014-11-13 | — | — | WO | claimed |
| WO-2014175444-A1 | ANTI-NLRR1 ANTIBODY | 千葉県 (JP) | 2014-10-30 | — | — | WO | claimed |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2013-09-12 | — | — | US | claimed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025101807-A1 | TREATMENT OF GLIOMAS WITH CHIMERIC ANTIGEN RECEPTOR T CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12268715-B2 | Method for producing biological tissue-like structure | Orizuru Therapeutics, Inc. (JP) | 2025-04-08 | — | — | US | disclosed |
| US-20250074981-A1 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-03-06 | — | — | US | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1976529-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007089445-A2 | ANG2 AND VEGF INHIBITOR COMBINATIONS | AMGEN INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216288-A1 | Combinations for the treatment of cancer | TP53, VHL, FOLR2 | FGFR1 646/4885KDR 2043/4885PDGFRB 737/4885 |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | FGF2, FGF1, FGFR2 | FGFR1 4/4885KDR 130/4885PDGFRB 59/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | FGFR1 3001/4885KDR 4542/4885PDGFRB 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.